Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05394519 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
NCT05394519 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 1,200 participants.
The verdict
NCT05394519, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
Study Summary
This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance. The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.
Interventions
- DRUG Semaglutide
- DRUG Cagrilintide
- DRUG Placebo cagrilintide
- DRUG Placebo semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2025-02-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05394519
The ClinicalTrials.gov registry entry for NCT05394519 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Semaglutide is the first listed.
NCT05394519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05394519 about?
NCT05394519 is a clinical study titled "A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight". This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance. The study will last for about 1½ years. Women cannot ...
What is the current status of trial NCT05394519?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2023-02-01. Estimated completion is 2025-02-03.
What interventions are being tested in trial NCT05394519?
The interventions under investigation include: Semaglutide (DRUG), Cagrilintide (DRUG), Placebo cagrilintide (DRUG), Placebo semaglutide (DRUG).
Who is sponsoring clinical trial NCT05394519?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.